Cetuximab Concomitant with Second-Line Radiation Therapy in Patients with Locally Advanced Recurrent Squamous Cell Head and Neck Cancer

Akmansu, Müge; Büyükberber, Süleyman; Iren, Sevilay; Demirci, Umut; Kanyılmaz, Gül; Coşkun, Uğur; Bora, Hüseyin

doi:10.1159/000323204

Cited by 1 publication

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Promising efficacy data with acceptable toxicity were reported with reirradiation and cetuximab in a small series of studies of patients with locoregional recurrent and inoperable SCCHN 61–64. Balermpas et al62 treated 18 patients with an inoperable recurrence of SCCHN after prior adjuvant or definitive RT and simultaneous or sequential cisplatin-based chemotherapy for primary SCCHN, with cetuximab and RT (1.8 Gy/fraction/day over 5–6 weeks resulting in a median total dose of 50.4 Gy).…”

Section: Efficacy Studies Including Any Comparative Studiesmentioning

confidence: 97%

See 1 more Smart Citation

Cetuximab: its unique place in head and neck cancer treatment

Specenier¹,

Vermorken²

2013

BTT

View full text Add to dashboard Cite

Head and neck cancer is the sixth most common cancer worldwide. At present, globally about 650,000 new cases of squamous cell carcinoma of the head and neck (SCCHN) are diagnosed each year. The epidermal growth factor receptor (EGFR) is almost invariably expressed in SCCHN. Overexpression of the EGFR is a strong and independent unfavorable prognostic factor in SCCHN. Cetuximab is a chimeric monoclonal antibody, which binds with high affinity to the extracellular domain of the human EGFR, blocking ligand binding, resulting in inhibition of the receptor function. It also targets cytotoxic immune effector cells towards EGFR-expressing tumor cells (antibody dependent cell-mediated cytotoxicity). The addition of cetuximab to radiotherapy (RT) improves locoregional control and survival when compared to RT alone. The addition of cetuximab to platinum-based chemoradiation (CRT) is feasible but does not lead to an improved outcome. Cetuximab plus RT has never been compared prospectively to CRT, which therefore remains the standard treatment for patients with locoregionally advanced SCCHN for whom surgery is not considered the optimal treatment, provided they can tolerate CRT. The addition of cetuximab to platinum-based chemotherapy prolongs survival in patients with recurrent or metastatic SCCHN. The combination of a platinum-based regimen and cetuximab should be considered as the standard first line regimen for patients who can tolerate this treatment.

show abstract

Section: Efficacy Studies Including Any Comparative Studiesmentioning

confidence: 97%

“…Akmansu et al61 reirradiated nine patients with doses ranging between 20–70 Gy with concomitant cetuximab. During RT, four patients had grade 2 and five patients had grade 3 skin toxicity.…”

Section: Efficacy Studies Including Any Comparative Studiesmentioning

confidence: 99%

Cetuximab: its unique place in head and neck cancer treatment

Specenier¹,

Vermorken²

2013

BTT

View full text Add to dashboard Cite

show abstract

Cetuximab Concomitant with Second-Line Radiation Therapy in Patients with Locally Advanced Recurrent Squamous Cell Head and Neck Cancer

Cited by 1 publication

References 23 publications

Cetuximab: its unique place in head and neck cancer treatment

Cetuximab: its unique place in head and neck cancer treatment

Contact Info

Product

Resources

About